Cytiva

Aiming to improve exosome purification process that is currently slowing adoption of promising gene therapies and other new modalities.

Silica-coated superparamagnetic beads for nucleic acid isolation deliver high purity DNA for NGS applications.

High-volume laboratories must keep analytic instruments running reliably while producing quality data. This means laboratory managers and technicians must ensure their instruments are performing optimally around the clock.

In food safety, chemical manufacturing and environmental testing labs, filtration of the sample and mobile phase prior to analysis helps reduce overall instrument wear and removes any particles that may interfere with the chromatogram.

In the quest for therapeutic or analytical antibodies, it is crucial to carefully select antibodies based on their kinetics, affinity, specificity and biophysical attributes. Antibody screening plays a pivotal role in identifying cell clones that generate antibodies suited to a specific purpose, often challenging these antibodies with a known antigen.

Sera-Mag™ oligo (dT)-coated magnetic particles have very high, specific poly A+ binding capacity. They remove 90% or more of mRNA from total RNA with just one extraction in applications such as RT-PCR, cDNA library construction, cDNA microarrays, affinity purification, primer extension, and subtractive hybridization.

In food safety, chemical manufacturing and environmental testing labs, the need to consistently generate high-quality data means that managers, scientists and technicians must ensure their instruments are performing optimally around the clock.

Each of your molecular or immunoassay development projects is unique. So, you need solutions tailored to your specific needs.

While magnetic beads provide a faster and easier solution than more complex, conventional methods, sometimes off-the-shelf solutions do not always offer the specificity or binding capacity required.

It is expected that within four to five years, biologics will comprise over half of the 100 top selling drugs on the market. However, the high cost and complexity of biotherapeutic development, as well as a dynamic regulatory landscape, still poses challenges to drug developers.